Hepatobiliary excretion of cysteinyl leukotrienes in three experimental models of acute hepatic injury
- 20 Downloads
The acute phase response to chemically-induced organ damage involves inflammation and the production of leukotrienes. The liver ordinarily takes up, metabolizes and excretes into bile cysteinyl leukotrienes, but the effect of hepatic injury on these processes is unknown. The hepatic uptake and biliary excretion of LTC4 was studied in male Sprague-Dawley rats after exposure to either streptozotocin (45 mg/kg iv 30 days before experimentation), estradiol-17 β-valerate (1mg/kg sc once a week for 3 weeks) or lipopolysaccharide/d-galactosamine (33 μg/kg ip; 300 mg/kg ip at 6 h and 3 h, respectively, before experimentation). Acute liver injury is produced by these treatment paradigms. Glucose concentrations and activities of several marker enzymes in plasma were measured to demonstrate hepatic injury. Biliary excretion of3H-LTC4 was similar to normal control rats in the three types of acute liver injury. Bile flow rates after3H-LTC4 injection were reduced in lipopolysaccharide-pretreated rats and increased in estradiol-treated animals. Total biliary excretion of leukotrienes was not altered in any disease group. Thus, these models of acute hepatic injury do not appear to influence the hepatobiliary clearance of leukotrienes.
Key wordsLeukotrienes Streptozotocin Estradiol Lipopolysaccharide Galactosamine
Unable to display preview. Download preview PDF.
- Krell H. Eicosanoid and bile secretion. In: Siegers CP, Watkins JB III, editors. Biliary Excretion of Drugs and Other Chemicals vol 8/4. Stuttgart: Fischer, 1991:435–54.Google Scholar
- Richards CD, Gauldie J. Role of cytokines in acute-phase response. In: Aggarwal BB, Puri RK, editors. Human cytokines: their role in disease and therapy. Boston: Blackwell, 1995:253–96.Google Scholar
- Andus T, Holstege A. Role of cytokines in hepatic and hepatobiliary disease. In: Aggarwal BB, Puri RK, editors. Human cytokines: their role in disease and therapy. Boston: Blackwell, 1995:623–40.Google Scholar
- Gallin JI, Goldstein IM, Synderman R. Overview. In: Gallin JI, Goldstein IM, Synderman R, editors. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1988:1–3.Google Scholar
- Fallon MB, Anderson JM, Boyer JL. Intrahepatic cholestasis. In: Schiff L, Schiff ER, editors. Diseases of the Liver, vol. 1. Philadephia: Lippincott, 1993:343–61.Google Scholar
- Kolb H, Kronck KD. Lessons from the low-dose streptozotocin model in mice. Diabet Rev 1993;1:116–26.Google Scholar
- Burkart V, Kolb H. Protection of islet cells from inflammatory cell death in vitro. Clin Exper Immunol 1993;33:273–8.Google Scholar
- Reitman S, Frankel S. A colorimetric determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am J Pathol 1957;28:56–63.Google Scholar
- White WL, Erickson MM, Stevens SC, editors. Chemistry for the Clinical Laboratory. St. Louis: CV Mosby, 1976:228–32.Google Scholar
- Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.Google Scholar
- Utili R, Abernathy CO, Zimmerman HJ. Cholestatic effects of Escherichia coli endotoxin on the isolated perfused rat liver. Gastroenterol 1976;70:248–53.Google Scholar